Lupin Limited (NSE:LUPIN)
2,265.00
-35.00 (-1.52%)
Aug 11, 2026, 1:00 PM IST
Lupin Revenue
Lupin had revenue of 82.77B INR in the quarter ending June 30, 2026, with 32.04% growth. This brings the company's revenue in the last twelve months to 299.67B, up 28.19% year-over-year. In the fiscal year ending March 31, 2026, Lupin had annual revenue of 279.58B with 23.12% growth.
Revenue (ttm)
299.67B
Revenue Growth
+28.19%
P/S Ratio
3.47
Revenue / Employee
11.52M
Employees
26,021
Market Cap
1.04T
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2026 | 279.58B | 52.50B | 23.12% |
| Mar 31, 2025 | 227.08B | 26.97B | 13.48% |
| Mar 31, 2024 | 200.11B | 33.69B | 20.25% |
| Mar 31, 2023 | 166.42B | 2.36B | 1.44% |
| Mar 31, 2022 | 164.05B | 12.43B | 8.19% |
| Mar 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Aurobindo Pharma | 349.35B |
| Cipla | 280.68B |
| Zydus Lifesciences | 271.48B |
| Glenmark Pharmaceuticals | 177.37B |
| Mankind Pharma | 147.38B |
| Alkem Laboratories | 147.12B |
| Divi's Laboratories | 112.30B |
| Ipca Laboratories | 96.47B |
Lupin News
- 3 days ago - Lupin Transcript: Q1 26/27 - Transcripts
- 3 days ago - Lupin Quarterly report: Q1 2027 - Filings
- 3 days ago - Lupin Slides: Q1 2027 - Filings
- 20 days ago - Lupin Transfers Two Oncology Assets To Kaveri Therapeutics - Nasdaq
- 5 weeks ago - Lupin receives EIR from U.S. FDA for Somerset facility with VAI classification - Business Upturn
- 5 weeks ago - Lupin receives EMA approval for NaMuscla expansion for paediatric use - Business Upturn
- 6 weeks ago - Lupin Gets Tentative FDA Nod For Enzalutamide Tablets - Nasdaq
- 6 weeks ago - Lupin Wins FDA's Tentative Approval For Enzalutamide Tablets Across Multiple Strengths - Nasdaq